$Recursion Pharmaceuticals(RXRX.US) conducted a round of research based on the most powerful Market Research Skills currently available. Claude Code ran for about 40 minutes, calling openrouter's API to process a lot of data. (This report cost me about $10.) The report is very long, so I extracted the final conclusion for investors, and the investment recommendation is confirmed.

Rating: Moderate Buy

Target Price: $9.80 (Expected) | $15-25 (Bullish Scenario)

Risk Tolerance: High — Suitable only for investors with strong risk appetite

Position: Small position (2-5% of portfolio)

Time Frame: 2-5 years holding (awaiting clinical validation)

Catalyst Watchlist:

2H 2025: First clinical readouts (1-2 out of 7)

2026: Multiple Phase II readouts completed

2027: First Phase III initiation/data

2028-2030: Potential FDA approval

Investor Type:

✅ High-risk/high-reward seekers

✅ Biotech/pharma sector experts

✅ Long-term holders (2-5 year horizon)

✅ Diversified portfolio (RXRX as a small satellite position)

❌ Risk-averse investors

❌ Investors needing income/dividends

❌ Short-term traders